Increased Demand for Anti-Id Antibodies
Evaluating pharmacokinetics or tissue distribution of therapeutic antibodies requires methods that distinguish an administered therapeutic antibody from endogenous immunoglobulins in patient samples. For humanized and fully-human therapeutic antibodies, it is especially difficult to find reagents that can distinguish these antibodies from the endogenous immunoglobulins they closely resemble. Monoclonal anti-idiotypic antibodies (anti-Ids) are ideal reagents for this purpose as they can recognize unique antigenic determinants on the V-regions of therapeutic antibodies with no cross-reactivity with unrelated antibodies in patients’ samples.
As the leading supplier of custom anti-Id development services to the biopharmaceutical industry, QED Bioscience has successfully developed monoclonal anti-Id antibodies for many organizations. If your therapeutic antibody programs require anti-Id antibodies to evaluate biodistribution, clearance, or immunogenicity, call QED. We’ll gladly discuss your requirements with you under strict confidentiality.